Are You Suffering from Brexit Fatigue?
The uncertainty surrounding the UK’s future with Europe is having a measurable effect on the pharma industry (and many others). But I’m afraid to say the end is nowhere in sight.
James Strachan | | Quick Read
Last month marked three years since the UK voted to leave the European Union. A great deal has happened in British politics in those three years and yet, the more things change, the more they stay the same. We still do not know how the Brexit process will end – but it’s not looking great.
As Steve Bates, CEO of the UK BioIndustry Organisation, said in June, the risk of “no deal” has risen in recent weeks (1). Parliament has rejected the Withdrawal Agreement (WA) on three occasions; EU leaders have made it clear that there will be no renegotiation of the WA, nor will they consider another Article 50 extension for the purpose of reopening negotiations on the WA. Meanwhile, both candidates for Prime Minister have promised to renegotiate the WA and, if the EU isn’t forthcoming, to leave the EU on October 31 without a deal.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine